Nexalin Technology (NXL) Return on Capital Employed Growth (1y) (2023 - 2026)
Nexalin Technology (NXL) Return on Capital Employed Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.36 Bn | 175.06 Bn | 6.27 Bn | -81.00 |
| 2 | Stryker | 128.86 Bn | 125.99 Bn | 3.81 Bn | -1,390.00 |
| 3 | Medtronic | 108.02 Bn | 98.80 Bn | 6.41 Bn | 39.00 |
| 4 | Boston Scientific | 68.21 Bn | 66.76 Bn | 3.61 Bn | 141.00 |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn | -110.00 |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 658.00 |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn | -3,185.00 |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 24.11 Bn | 20.99 Bn | 2.07 Bn | 125.00 |
| 10 | Nexalin Technology | 9.02 Mn | 6.31 Mn | 13,133.00 | 3,781.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,781.00 |
| Dec 31, 2025 | -2,519.00 |
| Sep 30, 2025 | 4,774.00 |
| Jun 30, 2025 | 10,448.00 |
| Mar 31, 2025 | -7,126.00 |
| Dec 31, 2024 | -2,703.00 |
| Sep 30, 2024 | -7,626.00 |
| Jun 30, 2024 | -26,163.00 |
| Mar 31, 2024 | -17,899.00 |
| Dec 31, 2023 | -12,706.00 |